KA
BMY.RT

Kintegral Advisory’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Kintegral Advisory’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,299
Closed -$12K – 269
2020
Q4 		$12K Hold
17,299
– – ﹤0.01% 267
2020
Q3 		$39K Hold
17,299
– – 0.01% 266
2020
Q2 		$62K Hold
17,299
– – 0.01% 266
2020
Q1 		$66K Hold
17,299
– – 0.01% 261
2019
Q4 		$52K Buy
+17,299
New +$45K 0.01% 267

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Kintegral Advisory's BMY.RT Position: Q1 2021 in Review

Kintegral Advisory sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 17,299 shares — an estimated $12K sold.

Kintegral Advisory first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $66K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Kintegral Advisory reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Kintegral Advisory sold 17,299 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $12K.
  • Kintegral Advisory first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Kintegral Advisory's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $66K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Kintegral Advisory's 13F filing for Q1 2021, filed 13 May 2021.